Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics


Deciphera Pharmaceuticals, Inc. (DCPH)

Today's Latest Price: $55.19 USD

1.50 (2.79%)

Updated Jun 5 4:00pm

Add DCPH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

DCPH Stock Summary

  • DCPH's went public 2.69 years ago, making it older than just 8.45% of listed US stocks we're tracking.
  • With a price/sales ratio of 123.01, Deciphera Pharmaceuticals Inc has a higher such ratio than 97.84% of stocks in our set.
  • With a year-over-year growth in debt of 780.78%, Deciphera Pharmaceuticals Inc's debt growth rate surpasses 97.59% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Deciphera Pharmaceuticals Inc, a group of peers worth examining would be EIDX, RCUS, EPZM, SGMO, and NTLA.
  • Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Daily Price Range
DCPH 52-Week Price Range

DCPH Stock Price Chart More Charts


DCPH Price/Volume Stats

Current price $55.19 52-week high $71.11
Prev. close $53.69 52-week low $19.88
Day low $54.06 Volume 542,121
Day high $56.46 Avg. volume 576,671
50-day MA $50.61 Dividend yield N/A
200-day MA $49.28 Market Cap 3.08B

Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio


Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.


DCPH Latest News Stream


Event/TimeNews Detail
Loading, please wait...

DCPH Latest Social Stream


Loading social stream, please wait...

View Full DCPH Social Stream

Latest DCPH News From Around the Web

Below are the latest news stories about Deciphera Pharmaceuticals Inc that investors may wish to consider to help them evaluate DCPH as an investment opportunity.

The Debate Is Over: This Cancer Stock Is Winning the GIST Race

Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.

Yahoo | June 3, 2020

Deciphera Prepares To Collect Revenue After First FDA Approval: 'We Are Well-Positioned'

After 17 years of clinical work, Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) finally has a marketable product. The Food and Drug Administration approved Qinlock as a fourth-line treatment of gastrointestinal stromal tumors earlier this month. The kinase inhibitor will be Deciphera’s first sustainable revenue generator, possibly boasting the $32,000-per-month price tag of peer therapies.Yet Deciphera isn’t yet projecting profitability. “We are not yet focused on a real path to profitability,” CEO Steve Hoerter told Benzinga, adding that the practice is common across the industry. “We’re focused on investing capital in the programs we have and getting those programs to important value inflection points as we generate additional data.” The company has “a number of places to invest,” he s...

Benzinga | May 29, 2020

Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific Program

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of data from the endometrial cancer cohort of Part 2 of its ongoing Phase 1b/2 clinical trial of rebastinib, the Company’s investigational orally administered, potent and selective inhibitor of the TIE-2 kinase, in combination with paclitaxel. The presentation, titled "An open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel in a dose expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer" (abstract 6085; poster 256), will be featured during a poster session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.

Yahoo | May 29, 2020

Deciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ASCO 2020 Virtual Scientific Program

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of quality of life and certain safety results from the INVICTUS pivotal Phase 3 study evaluating QINLOCK™ (ripretinib) in adult patients with fourth-line advanced gastrointestinal stromal tumor (GIST). These results were presented as part of the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.

Yahoo | May 29, 2020

Deciphera Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 2:00 PM ET. The conference will be held in a virtual meeting format.

Yahoo | May 27, 2020

Read More 'DCPH' Stories Here

DCPH Price Returns

1-mo 0.16%
3-mo 5.26%
6-mo 0.47%
1-year 151.78%
3-year N/A
5-year N/A
YTD -11.33%
2019 196.52%
2018 -7.41%
2017 N/A
2016 N/A
2015 N/A

Continue Researching DCPH

Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:

Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9296 seconds.